Norgestimate/Ethinyl Estradiol Oral Tablets
Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
    Description

    Special Notice DEPT OF DEFENSE is modifying contract SPE2D220D0090 to correct an administrative error for the procurement of Norgestimate/Ethinyl Estradiol Oral Tablets. Norgestimate/Ethinyl Estradiol Oral Tablets are typically used for contraception and hormone replacement therapy.

    Point(s) of Contact
    Files
    Title
    Posted
    Lifecycle
    Title
    Type
    Special Notice
    Similar Opportunities
    Norgestimate/Ethinyl Estradiol Oral Tablets
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking Norgestimate/Ethinyl Estradiol Oral Tablets. These tablets are typically used for oral contraception.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is soliciting offers for the supply of Norgestimate/Ethinyl Estradiol Tablets, a pharmaceutical product essential for oral contraceptive use. The procurement aims to establish a contract that outlines specific supply requirements, estimated quantities for multiple option years, and compliance with federal regulations, including ethical conduct and labor standards. This solicitation is critical for ensuring the availability of these contraceptive medications to support military personnel and their families. Interested contractors must submit their offers via the Defense Logistics Agency Internet Bid Board System (DIBBS) by January 21, 2025, and are encouraged to contact Kyle Lewicki at kyle.lewicki@dla.mil or Jason C. Wray at Jason.Wray@dla.mil for further information.
    Dextroamphetamine/Amphetamine National Contract
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is a procurement notice from the DEFENSE LOGISTICS AGENCY, specifically the DLA TROOP SUPPORT office. This notice falls under the category of MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES with a PSC code of 6515. The primary contact for this contract is Denise Taubman, who can be reached at DENISE.TAUBMAN@DLA.MIL or 215-737-8677. The notice describes an amendment, P00006, which incorporates additional clauses to the existing contract.
    Metformin HCL ER
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Metformin HCL ER. Metformin HCL ER is a drug used to treat type 2 diabetes. This procurement is being conducted by DLA TROOP SUPPORT. For more information, contact Christopher Newman at christopher.newman@dla.mil or 2157372905.
    Finasteride Tablets
    Active
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Finasteride Tablets. Finasteride Tablets are typically used for the treatment of male pattern hair loss and benign prostatic hyperplasia. This procurement is for the incorporation of new clauses into an existing contract.
    Metformin HCL
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Pantoprazole DR Tablets
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE Pantoprazole DR Tablets: The Defense Logistics Agency is planning to issue a national requirements contract for Pantoprazole DR Tablets. These tablets, available in 20MG and 40MG strengths, will be provided in 90 and 1000 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The tablets will be purchased by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the solicitation. Interested parties can find more information on the DLA Bid Board System and Beta Sam.Gov websites. The solicitation is projected to be issued in September 2021.
    Fexofenadine HCL Follow On MOD P00002
    Active
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Fexofenadine HCL Follow On MOD P00001. Fexofenadine HCL is a drug used to relieve symptoms of seasonal allergies such as runny nose, sneezing, itchy or watery eyes, and itching of the nose or throat. This procurement is for NDC changes. For more information, please contact Catherine Gilbert at catherine.gilbert@dla.mil or 2157374778.
    ESCITALOPRAM OXALATE PRE SOLICITATION SPE2D218R0022 CANCELLED
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is cancelling the pre-solicitation notice for the procurement of Escitalopram Oxalate Tablets. No solicitation will be issued under this pre-solicitation number SPE2D2-18-R-0022. Escitalopram Oxalate Tablets are typically used as a medication for the treatment of depression and anxiety disorders.
    SPE2D220R0063 BUPROPION XL AMENDMENT 0002
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking BUPROPION XL. This procurement is for drugs and biologicals under PSC code 6505. The primary contact for this procurement is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778) and the secondary contact is Denise Taubman (denise.taubman@dla.mil, 2157376877). The notice includes Amendment 0002, which incorporates telecommunication clauses. The solicitation is not reopened and the closing date is not extended. BUPROPION XL is typically used for medical purposes.